No Detail Found!

Effectiveness of Moxifloxacin in the Management of Tuberculous Meningitis: a Pilot Study.

Author(s)
Riaz Muhammad Department of Medicine, Lady Reading Hospital, Medical Teaching Institution, Peshawar – Pakistan
Zafar Ali Department of Medicine, Lady Reading Hospital, Medical Teaching Institution, Peshawar – Pakistan
Muhammad Abdur Rahman Afridi Department of Medicine, Lady Reading Hospital, Medical Teaching Institution, Peshawar – Pakistan
Muhammad Asghar Department of Medicine, Lady Reading Hospital, Medical Teaching Institution, Peshawar – Pakistan
Ali Sebtain Department of Medicine, Lady Reading Hospital, Medical Teaching Institution, Peshawar – Pakistan
Sajid Hussain Department of Medicine, Lady Reading Hospital, Medical Teaching Institution, Peshawar – Pakistan
Ejaz Ahmad Department of Medicine, Lady Reading Hospital, Medical Teaching Institution, Peshawar – Pakistan
Intekhab Alam Department of Medicine, Lady Reading Hospital, Medical Teaching Institution, Peshawar – Pakistan
Abstract
Objective: To determine the effectiveness of moxifloxacin as fourth drug in the management of tuberculous meningitis (TBM). Methodology: This hospital based comparative clinical trial was done as pilot study from January 2016 to December 2017. The study was carried out on 43 patients with TBM. Moxifloxacin based regimen (group I) versus standard treatment for tuberculous meningitis (group II) were compared. Computer software, SPSS version 21.0, was used for data entry and analysis. Statistical significance was considered at p value <0.05. Results: Out of 43 patients, there were 15 (34.9%) males and 28 (65.1%) females. Age of the patients ranged from 13 to 80 years (mean 31.418 ±18.62 years). Fever, headache, vomiting and altered level of consciousness was present in 38 (88.4%); neck stiffness in 39 (90.69%) and neurological deficit was present in 18 (41.9%) patients. Leptomeningeal enhancement was the most frequent radiological finding found in 13 (30.2%) patients. Overall improvement occured in 38 (88.37%) of patients. In group I, 21/22 (95.45%) patients and in group II, 17/21 (80.95%) patients improved, (p value 0. 158). Till 3rd day of commencement of treatment, 11/21 (52.38%) patients recovered in group I while 02/17 (11.76%) patients recovered in group II. Conclusion: Moxifloxacin based regimen was associated with an early recovery (within 03 days of commencement of treatment) in a significant number of patients with TBM.
Publication Details
Page(s) 137-143
DOI DOI not available
Published Journal: Journal of Postgraduate Medical Institute, Volume: 32, Issue: 2, Year: 2018

Request the full text from PASTIC

References
World Health Organization. Global tuberculosis re­port. Geneva: WHO; 2014. Available at: http://www. who.int/tb/publications/global_report/gtbr14_ex­ecutive_summary.pdf
PhypersM,HarrisT,PowerC.,,2006,CNS tuberculosis: a longitudinal analysis of epidemiological and clinical features,Int J Tuberc Lung Dis,10,99-103
AbdelmalekR,KanounF,KilaniB,TiouiriH,ZouitenF,GhoubantiniA,,2006,Tuberculous meningitis in adults: MRI contribution to the diagnosis in 29 patients,Int J Infect Dis,10,372-7
Hoang MaiNT,ThwaitesGE,,2016,The current pharmacological landscape of tuberculous meningitis: where to next?,Expert Rev Clin Pharmacol,9,625-7
ThwaitesGE,Van ToornR,SchoemanJ,,2013,Tuberculous meningitis: more questions, still too few answers,Lancet Neurol,12,999-1010
TaiMLS,,2013,Tuberculous meningitis: diagnostic and radiological features, pathogenesis and biomarkers,Neuro sci Med,4,101-7
World Health,,2010,Organization. Guidelines for treatment of tuberculosis (4th ed),WHO;,,147-
,2010,The chemotherapy of tuberculous meningitis in children and adults,Tuberculosis (Edinb),90,375-92
EllardGA,HumphriesMJ,AllenBW,,1993,Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis,Am Rev Respir Dis,148,650-5
RuslamiR,GaniemAR,DianS,AprianiL,AchmadTH,van der VenAJ,,2013,Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomized controlled phase 2 trial,Lancet Infect Dis,13,27-35
LolachiS,JanssensJP,AdlerDL,,2017,Tuberculous meningitis,what's new? J Neuro infect Dis,8,2-
LubaschA,KellerI,BornerK,KoeppeP,LodeH,,,Comparative pharmacokinetics of ciprofloxacin,,,,-
ShandilRK,JayaramR,KaurP,GaonkarS,SureshBL,MaheshBN,,2007,Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy,Antimicrob Agents Chemother,51,576-82
BurmanWJ,GoldbergS,JohnsonJL,MuzanyeG,EngleM,MosherAW,,2006,Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis,Am J Respir Crit Care Med,174,331-8
AlmeidaD,NuermbergerE,TyagiS,BishaiWR,GrossetJ.,,2007,In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis,Antimicrob Agents Chemother,51,4261-6
VanTTT,FarrarJ,,2014,-nervous-system-tuberculosis,,68,2-3
WasayM,FarooqS,KhowajaZA,BawaZA,AliSM,,2014,Cerebral infarction and tuberculoma in central nervous system tuberculosis: frequency and prognostic implications,J Neurol Neurosurg Psychiatry,85,1260-4
SheuJJ,YuanRY,YangCC,,2009,Predictors for outcome and treatment delay in patients with tuberculous meningitis,Am J Med Sci,338,134-9
GillespieSH,CrookAM,McHughTD,MendelCM,MeredithSK,MurraySR,,2014,Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis,N Engl J Med,371,1577-87
SpigelmanMK,,2007,New tuberculosis therapeutics: a growing pipeline,J Infect Dis,196,S28-34
TakiffH,GuerreroE.,,2011,Current prospects for the fluoroquinolones as first-line tuberculosis therapy,Antimicrob Agents Chemother,551,5421-9
FouadM,GallagherJC,,2011,Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis,Ann Pharmacother,45,1439-44
KanellakopoulouK,PagoulatouA,StroumpoulisK,VafiadouM,KranidiotiH,GiamarellouH,,2008,Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect,J Antimicrob Chemother,61,1328-31
AlffenaarJW,van AltenaR,BokkerinkHJ,LuijckxGJ,van SoolingenD,AanoutseRE,,2009,Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis,Clin Infect Dis,49,1080-2
Ostergaard , C,SorensenTK,KnudsenJD,Frimodt-Moller N,,1998,Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits,Antimicrob Agents Chemother,42,1706-12
Rodriguez-CerratoV,McCoigCC,MichelowIC,GhaffarF,JafriHS,HardyRD,,2001,Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis,Antimicrob Agents Chemother,45,3092-7
CondeMB,EfronA,LoredoC,De SouzaGR,GraçaNP,CezarMC,,2009,Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomized, controlled phase II trial,Lancet,373,1183-9
RodríguezJC,RuizM,ClimentA,RoyoG.,,2001,In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis,Int J Antimicrob Agents,17,229-31
AlffenaarJW,de VriesPM,LuijckxGJ,van SoolingenD,van der WerfTS,van AltenaR.,,2008,Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis,Antimicrob Agents Chemother,52,2293-5
NijlandHM,RuslamiR,SurotoAJ,BurgerDM,AlisjahbanaB,van CrevelR,,2007,Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis,Clin Infect Dis,45,1001-7
WeinerM,BurmanW,LuoCC,PeloquinCA,EngleM,GoldbergS,,2007,Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin,Antimicrob Agents Chemother,51,2861-6
NaidooA,NaidooK,McllleronH,EssackS,PadayatchiN.,,2017,A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis,J Clin Pharmacol,57,1369-86
DonaldPR,,2016,Chemotherapy for Tuberculous Meningitis,N Engl J Med,374,179-81
Te BrakeL,DianS,GaniemAR,RuesenC,BurgerD,DondersR,,2015,Pharmacokinetic/ pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis,Int J Antimicrob Agents,45,496-503
HeemskerkAD,BangND,MaiNT,,2016,Intensified antituberculosis therapy in adults with tuberculous meningitis,N Engl J Med,374,124-4
ThwaitesGE,BhavnaniSM,ChauTT,HammelJP,TörökME,Van WartSA,,2011,Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis,Antimicrob Agents Chemother,55,3244-53
0

Citations

0

Downloads

60

Views